JOHNSON & JOHNSON Q3 2025 Filing
Filed November 13, 2025
Portfolio Value
$503.7B
Holdings
20
Report Date
Q3 2025
Filing Type
13F-HR
All Holdings (20 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | PTGXProtagonist Therapeutics Inc. | 2,449,183 | $162.7B | 32.30% | |
| 2 | NBTXNanobiotix S.A. | 5,623,816 | $106.2B | 21.09% | |
| 3 | MGTXMeiraGTx Holdings plc | 6,641,064 | $54.7B | 10.85% | |
| 4 | RAPPRapport Therapeutics, Inc. | 1,784,517 | $53.0B | 10.52% | |
| 5 | CVRXCVRx, Inc. | 4,103,430 | $33.1B | 6.57% | |
| 6 | LEGNLegend Biotech Corporation | 814,586 | $26.6B | 5.27% | |
| 7 | CTNMContineum Therapeutics Inc. | 1,979,173 | $23.3B | 4.62% | |
| 8 | PRCTProcept BioRobotics Corporation | 357,939 | $12.8B | 2.54% | |
| 9 | XNCRXencor, Inc. | 748,062 | $8.8B | 1.74% | |
| 10 | ARWRArrowhead Pharmaceuticals, Inc. | 247,598 | $8.5B | 1.70% | |
| 11 | FATEFate Therapeutics, Inc. | 3,379,064 | $4.3B | 0.85% | |
| 12 | NMRANeumora Therapeutics, Inc. | 1,849,445 | $3.4B | 0.67% | |
| 13 | VORVor Biopharma, Inc. | 53,732 | $2.6B | 0.52% | |
| 14 | RLYBRallybio Corporation | 3,636,363 | $1.8B | 0.36% | |
| 15 | LYELLyell Immunopharma Inc. | 41,165 | $668.5M | 0.13% | |
| 16 | NNOXNano-X Imaging Ltd. | 158,852 | $587.8M | 0.12% | |
| 17 | FLBStandard BioTools Inc | 311,967 | $405.6M | 0.08% | |
| 18 | TORCEURAdicet Bio, Inc. | 364,472 | $295.3M | 0.06% | |
| 19 | PHGEBiomX Inc. | 96,866 | $50.9M | 0.01% | |
| 20 | SENS1GBPSenseonics Holdings, Inc. | 54,621 | $23.8M | 0.00% |